Cortexyme, Inc.

Cortexyme, Inc.

Cortexyme, Inc.

Overview
Date Founded

2012

Headquarters

269 East Grand Ave,South San Francisco, CA 94080

Type of Company

Public

Employees (Worldwide)

37

Industries

Biotechnology
Restaurants
Hospitals & Patient Services
Medical Support Services

Company Description

Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline comprises COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Contact Data
Trying to get in touch with decision makers at Cortexyme, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer, Co-Founder

Chief Operating Officer & Chief Financial Officer

Chief Scientific Officer & Director

Secretary, Chief Administrative & Legal Officer

Chief Accounting Officer

Executive Vice President, Research & Development

Vice President, CMC

Vice President, Regulatory & Quality

Vice President

Board of Directors

Chief Executive Officer, Co-Founder at Cortexyme, Inc.

President at Lamond Tomahawk Fund LP

Former Chief Operating Officer at Gilead Sciences, Inc.

Partner at Pfizer Venture Investments

Board Member & Lead Director at Albany Molecular Research, Inc.

Chief Financial Officer & Executive Vice President at Exelixis, Inc.

Chief Scientific Officer & Director at Cortexyme, Inc.

Paths to Cortexyme, Inc.
Potential Connections via
Relationship Science
You
Cortexyme, Inc.
Owners & Shareholders
Details Hidden

Pacific Heights Asset Management is the investment advisor to the Permanent Portfolio of funds, an investment company consisting of 4 distinct mutual funds: Permanent Portfolio, Short-Term Treasury Portfolio, Versatile Bond Portfolio, and Aggressive Growth Portfolio.Permanent Portfolio, designed as a core portfolio holding, seeks to preserve and increase the purchasing power value of each shareholder’s account over the long-term, regardless of current or future market conditions, through investments in an array of asset classes. It invests a fixed target percentage of its net assets in 6 diverse and non-correlated investment categories including gold, silver, Swiss franc assets, US and foreign real estate and natural resource stocks, aggressive growth stocks, and dollar assets such as US Treasury bills and bonds.Short-Term Treasury Portfolio seeks to earn high current income, consistent with safety and liquidity of principal. It invests at least 80% of its assets in direct debt obligations of the US Treasury. The remainder may be invested in US government agency securities. The portfolio invests primarily in US Treasuries with a dollar-weighted average portfolio maturity and duration of 0-3 year.Versatile Bond Portfolio seeks to earn high current income. Generally, it invests at least 80% of its assets in bonds, which may include debt securities of all types and of any maturity. It invests in bonds with a range of maturities from short- to long-term and does not attempt to maintain a pre-set average portfolio maturity or duration. It may invest in obligations of US and non-US issuers. Up to 50% of the portfolio may be invested in below investment grade bonds.Aggressive Growth Portfolio seeks to achieve high, long-term appreciation in the value of its shares. Typically, it invests in stocks and stock warrants of US and foreign companies that are expected to have a higher profit potential than the stock market and whose shares are valued primarily for potential growth in revenues, earnings, dividends or asset values rather than for current income. The portfolio holds stocks from at least 12 industry groups, including large-, mid- and small-cap companies. Pacific Heights looks for shares that are believed to be undervalued. The portfolio is intended to stay fully invested in stocks at all times.

Details Hidden

Ikarian Capital LLC is a multi-national private company headquartered in Dallas, TX. The firm provides investment advice. It was founded by Neil Tristan Shahrestani. Ikarian Capital LLC controls a large interest in TRACON Pharmaceuticals, Inc. (35.68 %).

Details Hidden

Ikarian Capital LLC is a multi-national private company headquartered in Dallas, TX. The firm provides investment advice. It was founded by Neil Tristan Shahrestani. Ikarian Capital LLC controls a large interest in TRACON Pharmaceuticals, Inc. (35.68 %).

Recent Transactions
Details Hidden

Cortexyme, Inc. issued USD Common Stock

Details Hidden

Cortexyme, Inc. raised money in a private placement transaction

Details Hidden

Cortexyme, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onCortexyme, Inc. issued USD Common Stock

Underwriter

Advised onCortexyme, Inc. issued USD Common Stock

Auditor

Advised onCortexyme, Inc. issued USD Common Stock

Legal Advisor

Advised onCortexyme, Inc. issued USD Common Stock

Attorney

Advised onCortexyme, Inc. issued USD Common Stock

Legal Advisor

Advised onCortexyme, Inc. issued USD Common Stock

Key Stats and Financials As of 2020
Market Capitalization
$1B
Total Enterprise Value
$677M
Earnings Per Share
$-2.63
Three Year Compounded Annual Growth Rate Of Revenue
0%
Debt TEV
0x
TEVNet Income
-8.81x
Total Equity
$172M
Total Debt
$446K
EBITDA
$-78.6M
Net Profit
$-76.8M
Revenue
$0
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
$350K
12/31/2014
Investors
Details Hidden

Verily Life Sciences LLC provides healthcare solutions for global markets. The firm specializes in healthcare, hardware, software, clinical studies, scientific research, disease management platforms, sensors, population health management and precision medicine. It develops tools to collect and organize health data. The company is headquartered in South San Francisco, CA.

Details Hidden

Pfizer Ventures invest in companies located across the globe, primarily in the US. The firm targets companies operating in the fields of therapeutic, neuroscience, diagnostics, drug delivery, pharmaceuticals and other technologies. It provides financing for seed, early and later capital requirements with an investment size of $10 million and also acts as a lead and co-investor. It takes minority interest and takes a seat on the board of directors.

Details Hidden

CWGI is the investment adviser to the American Funds Group, a family of 30 funds marketed to individuals exclusively through financial advisers and other intermediaries. American Funds are also used as investment vehicles for 401ks, other retirement plans, variable annuities and 529 college savings plans. The funds have the following characteristics: (1) a long-term, value-oriented approach; (2) long-established, global research; (3) a multiple portfolio counselor system that combines teamwork with individual accountability; (4) experienced, long-tenured investment professionals; and (5) a commitment to low operating expenses, among the lowest in the fund industry. CWGI uses a Multiple Portfolio Counselor System wherein the assets of each fund are divided into smaller, more manageable portions. Research analysts typically manage a segment as well, bringing their expertise directly to bear on the fund's results and portfolio counselors are free to make their own decisions. Investment decisions are based on internal research.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Biogen, Inc. Biotechnology - Canyon Country, CA

Biogen has some of the world’s best neurologists and neuroscientists. They engage with physicians and scientific leaders around the world with the aim to further medical research. Their focus on neuroscience, their deep scientific expertise and courage to take risks makes them leaders in the research and development of medicines to transform neuroscience to benefit society. Their technology and engineering capabilities create novel ways to seamlessly transition products from development to manufacturing with the intent of bringing their high-quality medicines to market faster. They respect the contributions of health care providers caring for people living with neurological diseases. They honor the important role of caregivers, families and friends who care about them.

Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Cortexyme, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Cortexyme, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Cortexyme, Inc..